{
  "abstract": "Prostate cancer is the most common cancer diagnosed in men. Metastatic castration-resistant prostate cancer (mCRPC) is associated with significant morbidity and mortality. The last decades have seen the introduction of multiple new therapeutic agents, such as androgen receptor pathway inhibitors, PARP inhibitors, new cytotoxic agents, and radioligand therapies. Further advancements are being made with immunotherapy utilising new molecular targets. As these treatments move earlier in the treatment pathway, determining the optimal treatment sequencing becomes the challenge. This review aimed to highlight established treatments, recent developments, and promising therapies in mCRPC.",
  "abstract_shown": true,
  "affiliations": [
    "Beatson West of Scotland Cancer Centre , ,"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Ilesha Ewart"
    },
    {
      "affs": [
        0
      ],
      "name": "Manreet Randhawa"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/2qxmkzz3s7byy.bib",
  "cited_by": 0,
  "doi": "10.3389/fendo.2026.1924299",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691727/?tool=EBI",
  "id": "2qxmkzz3s7byy",
  "issns": [
    "1664-2392"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13691727",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2740|Prostate Cancer Treatment and Research"
    ]
  ],
  "openalex": "W7221183698",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691727/pdf/?tool=EBI",
  "pmcid": "PMC13691727",
  "pmid": null,
  "published": "2026-10-09",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/2qxmkzz3s7byy.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:59Z",
      "native_id": "PMC:PMC13691727",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13691727"
    },
    {
      "first_seen": "2026-10-30T12:20:20Z",
      "native_id": "10.3389/fendo.2026.1924299",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fendo.2026.1924299/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:1664-2392",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "Prostate cancer: advancements in targeted therapies",
  "title_text": "Prostate cancer: advancements in targeted therapies",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:20Z",
  "url": "https://research.draconitic.com/paper/2qxmkzz3s7byy",
  "venue": "Frontiers in endocrinology",
  "versions": []
}